🇺🇸 FDA
Patent

US 11648318

Anti-transferrin receptor (TFR) antibody and uses thereof

granted A61KA61K2039/505A61K2039/54

Quick answer

US patent 11648318 (Anti-transferrin receptor (TFR) antibody and uses thereof) held by Dyne Therapeutics, Inc. expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K47/6807